WO2000071754A8 - Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors - Google Patents

Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors

Info

Publication number
WO2000071754A8
WO2000071754A8 PCT/US2000/014354 US0014354W WO0071754A8 WO 2000071754 A8 WO2000071754 A8 WO 2000071754A8 US 0014354 W US0014354 W US 0014354W WO 0071754 A8 WO0071754 A8 WO 0071754A8
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosing
preventing
methods
genetic
combination
Prior art date
Application number
PCT/US2000/014354
Other languages
French (fr)
Other versions
WO2000071754A1 (en
WO2000071754A3 (en
Inventor
William G Johnson
Edward Scott Stenroos
Original Assignee
Univ New Jersey Med
William G Johnson
Edward Scott Stenroos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New Jersey Med, William G Johnson, Edward Scott Stenroos filed Critical Univ New Jersey Med
Priority to EP00932767A priority Critical patent/EP1208227A1/en
Priority to CA002374540A priority patent/CA2374540A1/en
Priority to PCT/US2000/014354 priority patent/WO2000071754A1/en
Priority to MXPA01012201A priority patent/MXPA01012201A/en
Priority to AU50442/00A priority patent/AU5044200A/en
Publication of WO2000071754A1 publication Critical patent/WO2000071754A1/en
Publication of WO2000071754A8 publication Critical patent/WO2000071754A8/en
Publication of WO2000071754A3 publication Critical patent/WO2000071754A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • A61K31/714Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0012Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • C12N9/003Dihydrofolate reductase [DHFR] (1.5.1.3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Abstract

The present invention discloses a novel method for identifying an individual who may be susceptible to develop a developmental disorder. In one particular example, an individual is identified who is genetically susceptible to becoming schizophrenic. In addition, the present invention discloses a novel method for identifying individuals who are genetically susceptible to have offspring with a developmental disorder. Methods of diagnosing, preventing and treating developmental disorders such as schizophrenia are also provided.
PCT/US2000/014354 1999-05-25 2000-05-24 Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors WO2000071754A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP00932767A EP1208227A1 (en) 1999-05-25 2000-05-24 Methods for diagnosing, preventing and treating developmental disorders due to a combination of genetic and environmental factors
CA002374540A CA2374540A1 (en) 1999-05-25 2000-05-24 Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors
PCT/US2000/014354 WO2000071754A1 (en) 1999-05-25 2000-05-24 Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors
MXPA01012201A MXPA01012201A (en) 1999-05-25 2000-05-24 Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors.
AU50442/00A AU5044200A (en) 1999-05-25 2000-05-24 Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/318,448 US6210950B1 (en) 1999-05-25 1999-05-25 Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors
PCT/US2000/014354 WO2000071754A1 (en) 1999-05-25 2000-05-24 Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors

Publications (3)

Publication Number Publication Date
WO2000071754A1 WO2000071754A1 (en) 2000-11-30
WO2000071754A8 true WO2000071754A8 (en) 2001-03-08
WO2000071754A3 WO2000071754A3 (en) 2002-03-28

Family

ID=23238230

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/014354 WO2000071754A1 (en) 1999-05-25 2000-05-24 Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors

Country Status (6)

Country Link
US (1) US6210950B1 (en)
EP (1) EP1208227A1 (en)
AU (1) AU5044200A (en)
CA (1) CA2374540A1 (en)
MX (1) MXPA01012201A (en)
WO (1) WO2000071754A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566065B1 (en) 1994-05-26 2003-05-20 Mcgill University Method of diagnosing schizophrenia by detecting a mutation in the (MTHFR) gene
US6570062B1 (en) * 1997-07-21 2003-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US7378506B2 (en) * 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6548642B1 (en) * 1997-07-21 2003-04-15 Ohio University Synthetic genes for plant gums
US6639050B1 (en) 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6912492B1 (en) * 1999-05-25 2005-06-28 University Of Medicine & Dentistry Of New Jersey Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US6613763B2 (en) * 2001-04-20 2003-09-02 Mgi Applied Genomics Use of molindone to treat oppositional defiant disorder and conduct disorder
AU2002305384B2 (en) * 2001-05-04 2006-06-01 University Of Virginia Patent Foundation Method, apparatus, and computer program product for assessment of attentional impairments
US7101666B2 (en) * 2001-08-31 2006-09-05 Centre For Addiction And Mental Health Involvement of the BDNF gene in mood disorders
WO2003052093A1 (en) * 2001-12-19 2003-06-26 Bayer Healthcare Ag Regulation of human tetrahydrofolate dehydrogenase/cyclohydrolase
US7087233B2 (en) 2002-07-05 2006-08-08 Chee-Keung Chung Antimutagenic effects of Ganoderma lucidum spores
US20060252120A1 (en) * 2003-05-09 2006-11-09 Kieliszewski Marcia J Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
EP1711533B1 (en) * 2004-01-14 2013-12-11 Ohio University Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
AU2005223637A1 (en) * 2004-03-18 2005-09-29 University Of Virginia Patent Foundation Method, apparatus, and computer program product for stochastic psycho-physiological assessment of attentional impairments
CA2573918A1 (en) * 2004-04-19 2005-11-24 Ohio University Cross-linkable glycoproteins and methods of making the same
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US7790363B2 (en) * 2005-02-07 2010-09-07 Abbott Laboratories Inc. Diagnostic test for vitamin B12
WO2007008708A2 (en) * 2005-07-08 2007-01-18 Ohio University Methods of predicting hyp-glycosylation sites for proteins expressed and secreted in plant cells, and related methods and products
US20080058282A1 (en) * 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US20090326832A1 (en) * 2008-06-27 2009-12-31 Microsoft Corporation Graphical models for the analysis of genome-wide associations
WO2010002972A1 (en) * 2008-07-01 2010-01-07 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
GB2480773B (en) 2009-01-06 2013-12-11 Curelon Llc Compositions for the treatment of diarrhea caused by virulent E. coli infections
KR101694930B1 (en) 2009-01-06 2017-01-10 큐어론 엘엘씨 Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
EP2701733B1 (en) 2011-04-21 2019-04-03 Curemark, LLC Compounds for the treatment of neuropsychiatric disorders
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US20150335262A1 (en) * 2014-05-22 2015-11-26 New York University System, method and computer-accessible medium for the probabilistic determination of normal pressure hydrocephalus
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5085983A (en) * 1988-08-19 1992-02-04 City Of Hope Detection of human tumor progression and drug resistance
AU748442B2 (en) * 1997-07-01 2002-06-06 Cambia Vertebrate telomerase genes and proteins and uses thereof
AU768810B2 (en) * 1998-07-20 2004-01-08 Century Technology, Inc. Gene sequence variances with utility in determining the treatment of disease

Also Published As

Publication number Publication date
US6210950B1 (en) 2001-04-03
EP1208227A1 (en) 2002-05-29
CA2374540A1 (en) 2000-11-30
WO2000071754A1 (en) 2000-11-30
WO2000071754A3 (en) 2002-03-28
MXPA01012201A (en) 2002-07-02
AU5044200A (en) 2000-12-12

Similar Documents

Publication Publication Date Title
WO2000071754A8 (en) Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors
DE59401483D1 (en) GRAFTED POLYAMIDOAMINE AND GRAFTED POLYETHYLENIMINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS AN ADDITIONAL DETERGENT
WO1992017152A3 (en) Method for detecting and treating alzheimer's disease
HK1073430A1 (en) Treatment of central nervous system damage
AU2085201A (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
ATE252578T1 (en) 1,3-OXAZOLINE AND 1,3-THIAZOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS PESTOPTIC AGENTS
WO2001079458A3 (en) Polypeptides having haloperoxidase activity
AU2002366641A1 (en) Methods for inhibiting ocular processes
DE19983529T1 (en) Zinc stannate buffer layer having photovoltaic components and method for producing the same
EP0804548A4 (en) Patched genes and their use
DE69917716D1 (en) Protein-deamidative enzyme, gene coding therefor, method for the production and use thereof
DE69811200D1 (en) TEMPERED STEEL WITH EXCELLENT PREVENTION OF SECONDARY RECRISTALIZATION DURING CARBONING, METHOD FOR THE PRODUCTION THEREOF, SEMI-PRODUCT FOR PARTS TO BE CARBONED
DE59707078D1 (en) MONOOLEFINIC C 5-MONONITRILE, METHOD FOR THE PRODUCTION AND USE THEREOF
WO2001032876A3 (en) Compositions and methods for determining interactions of mitochondrial components, and for identifying agents that alter such interactions
AU2002356998A1 (en) Genetic markers associated with desirable and undesirable traits in horses, methods of identifying and using such markers
DK1900811T3 (en) Enriched cell populations in the central nervous system
DE69410181T2 (en) ALCOHOLIC AND OLEOPHOBIC, FLUORINE-BASED WETTING AGENTS AND METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
ATE474061T1 (en) METHOD FOR THE ENZYMATIC ENANTIOMER SEPARATION OF 3(R)- AND 3(S)-HYDROXY-1-METHYL-4-(2,4, 6-TRIMETHOXYPHENYL)-1, 2,3,6-TETRAHYDRO-PYRIDINE OR THE CARBOXIC ACID ESTERS
DE68917154D1 (en) C-TERMINUS AMIDATING ENZYME COMPOSITION, METHOD FOR THE PRODUCTION AND USE.
MX9600754A (en) An animal ear tag and method of application.
DE69924530D1 (en) POLYCARBONATE RESIN AND METHOD FOR THE PRODUCTION THEREOF
WO2002062205A3 (en) Methods for diagnosing and treating heart disease
WO1997035878A3 (en) The porcine heart fatty acid-binding protein encoding gene and methods to identify polymorphisms associated with body weight
WO2002080755A3 (en) Kits and methods for assessing oxidative stress
DE58905478D1 (en) GRINDING PIECE FOR CURRENT COLLECTORS AND METHOD FOR THE PRODUCTION THEREOF.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 48/2000 UNDER "PUBLISHED", REPLACE THE EXISTING TEXT BY "WITHOUT INTERNATIONAL SEARCH REPORT AND TO BE REPUBLISHED UPON RECEIPT OF THAT REPORT." AND REPLACE "A1" BY "A2"

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2374540

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2374540

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/012201

Country of ref document: MX

Ref document number: 515740

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 50442/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000932767

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000932767

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000932767

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP